

We claim:

1. An antibody that specifically binds to one or more epitopes of the laminin 5 γ 2 chain contained within SEQ ID NO: 6.
2. The antibody of claim 1, wherein the antibody specifically binds to one or
5 more epitopes of the laminin 5 γ 2 chain contained within SEQ ID NO:7.
3. The antibody of claim 1, wherein the antibody specifically binds to one or more epitopes of the laminin 5 γ 2 chain contained within SEQ ID NO:8.
4. The antibody of claim 1, wherein the antibody specifically binds to one or more epitopes of the laminin 5 γ 2 chain contained within SEQ ID NO: 9.
- 10 5. The antibody of claim 1, wherein the antibody specifically binds to one or more epitopes of the laminin 5 γ 2 chain contained within SEQ ID NO:10.
6. The antibody of claim 1, wherein the antibody specifically binds to one or more epitopes of the laminin 5 γ 2 chain contained within SEQ ID NO:11.
7. The antibody of claim 1, wherein the antibody specifically binds to one or
15 more epitopes of the laminin 5 γ 2 chain contained within SEQ ID NO:12.
8. The antibody of claim 1, wherein the antibody specifically binds to one or more epitopes of the laminin 5 γ 2 chain contained within SEQ ID NO:13.
9. The antibody of claim 1, wherein the antibody specifically binds to one or more epitopes of the laminin 5 γ 2 chain contained within SEQ ID NO:14.
- 20 10. The antibody of claim 1, wherein the antibody specifically binds to one or more epitopes of the laminin 5 γ 2 chain contained within SEQ ID NO:15.
11. The antibody of claim 1, wherein the antibody specifically binds to one or more epitopes of the laminin 5 γ 2 chain contained within SEQ ID NO:16.
12. The antibody of claim 1, wherein the antibody specifically binds to one or
25 more epitopes of the laminin 5 γ 2 chain contained within SEQ ID NO:17.
13. The antibody of claim 1, wherein the antibody specifically binds to one or more epitopes of the laminin 5 γ 2 chain contained within SEQ ID NO:18.
14. The antibody of claim 1, wherein the antibody specifically binds to one or more epitopes of the laminin 5 γ 2 chain contained within SEQ ID NO:19.
- 30 15. The antibody of claim 1, wherein the antibody specifically binds to one or more epitopes of the laminin 5 γ 2 chain contained within SEQ ID NO:20.

16. The antibody of claim 1, wherein the antibody specifically binds to one or more epitopes of the laminin 5 γ 2 chain contained within SEQ ID NO:21.
17. The antibody of claim 1, wherein the antibody specifically binds to one or more epitopes of the laminin 5 γ 2 chain contained within SEQ ID NO:22.
- 5 18. The antibody of claim 1, wherein the antibody specifically binds to one or more epitopes of the laminin 5 γ 2 chain contained within SEQ ID NO:23.
19. The antibody of claim 1, wherein the antibody specifically binds to one or more epitopes of the laminin 5 γ 2 chain contained within SEQ ID NO:24.
20. The antibody of claim 1, wherein the antibody specifically binds to one or
10 more epitopes of the laminin 5 γ 2 chain contained within SEQ ID NO:25.
21. The antibody of claim 1, wherein the antibody specifically binds to one or more epitopes of the laminin 5 γ 2 chain contained within SEQ ID NO:26.
22. The antibody of any one of claims 1-21, wherein the antibody is a monoclonal antibody.
- 15 23. The antibody of any one of claims 1-21 wherein the antibody is a humanized or fully human antibody.
24. The antibody of any one of claims 1-23 wherein the one or more epitopes comprise one or more linear epitopes.
25. The antibody of any one of claims 1-23 wherein the one or more epitopes
20 comprise one or more non-linear epitopes.
26. An isolated cell that produces the antibody of claim 22.
27. A pharmaceutical composition comprising the antibody of any one of claims 1-21 and a pharmaceutically acceptable carrier.
28. The pharmaceutical composition of claim 27 wherein the antibody is a
25 monoclonal antibody.
29. The pharmaceutical composition of claim 27 wherein the antibody is a humanized or fully human antibody.
30. The pharmaceutical composition of any one of claims 27-29, further comprising an additional anti-tumor agent.
- 30 31. A method for detecting the presence of invasive cells, comprising
 - (a) contacting a tissue with an antibody according to any one of claims 1-21 to form an immunocomplex between the antibody and a laminin 5 γ 2 epitope in the tissue; and

- (b) detecting formation of the immunocomplex, wherein the formation of the immunocomplex correlates with the presence of invasive cells in the tissue.
32. The method of claim 31 wherein the tumor tissue comprises a carcinoma.
33. A method for inhibiting tumor growth, comprising administering to a patient
5 with a tumor an amount effective to inhibit tumor growth of an antibody according to any one of claims 1-21.
34. The method of claim 33 wherein the tumor comprises a carcinoma.
35. The method of claim 33 wherein the method is used in combination with one or more of the following treatments:
- 10 (a) primary surgery for removing one or more tumors;
(b) secondary cytoreductive surgery;
(c) palliative secondary surgery;
(d) radiation therapy; and
(e) chemotherapy.
- 15 36. A method for inhibiting tumor metastasis, comprising administering to a patient with a tumor an amount effective to inhibit tumor metastasis of an antibody according to any one of claims 1-21.
37. The method of claim 36 wherein the tumor comprises a carcinoma.
38. The method of claim 36 wherein the method is used in combination with one
20 or more of the following treatments:
- (a) primary surgery for removing one or more tumors;
(b) secondary cytoreductive surgery;
(c) palliative secondary surgery;
(d) radiation therapy; and
25 (e) chemotherapy.
39. The method of any one of claims 31-38 wherein the antibody is a monoclonal antibody.
40. The method of any one of claims 31-38 wherein the antibody is a humanized or fully human antibody.
- 30 41. Use of an antibody according to any one of claims 1-21 for the preparation of a medicament for inhibiting tumor metastasis.
42. Use of an antibody according to any one of claims 1-21 for the preparation of a medicament for inhibiting tumor growth.

43. The use of claim 41 or 42 wherein the antibody is a monoclonal antibody.
44. The use of claim 41 or 42 wherein the antibody is a humanized or fully human antibody.
45. The use of any one of claims 41-44 wherein the tumor comprises a carcinoma.
- 5 46. The use of any one of claims 41-44 wherein the medicament is prepared for use in combination with one or more of the following treatments:
- (a) primary surgery for removing one or more tumors;
 - (b) secondary cytoreductive surgery;
 - (c) palliative secondary surgery;
 - 10 (d) radiation therapy; and
 - (e) chemotherapy.
47. An isolated polypeptide consisting of an amino acid sequence selected from the group consisting of SEQ ID NOS: 6-26.